$LPCN
Lipocine Inc.

2024 Q3 Form 10-Q Financial Statement

#000149315224030648 Filed on August 08, 2024

View on sec.gov

Income Statement

Concept 2024 Q3 2024 Q2
Revenue $89.57K
YoY Change
Cost Of Revenue
YoY Change
Gross Profit
YoY Change
Gross Profit Margin
Selling, General & Admin $1.045M $1.507M
YoY Change 0.5% 4.65%
% of Gross Profit
Research & Development $1.585M $1.875M
YoY Change -44.93% -25.46%
% of Gross Profit
Depreciation & Amortization $8.520K $8.510K
YoY Change -14.8% 5.19%
% of Gross Profit
Operating Expenses $2.630M $3.382M
YoY Change -32.92% -14.5%
Operating Profit -$2.630M -$3.293M
YoY Change -62.65% -16.76%
Interest Expense $273.6K $308.9K
YoY Change
% of Operating Profit
Other Income/Expense, Net $411.7K $224.4K
YoY Change 4.91% -44.86%
Pretax Income -$2.219M -$3.068M
YoY Change -66.64% -13.54%
Income Tax $481.00
% Of Pretax Income
Net Earnings -$2.219M -$3.069M
YoY Change -66.64% -13.53%
Net Earnings / Revenue -3426.15%
Basic Earnings Per Share -$0.41 -$0.57
Diluted Earnings Per Share -$0.44 -$0.56
COMMON SHARES
Basic Shares Outstanding 5.348M shares 5.348M shares
Diluted Shares Outstanding 5.348M shares 5.344M shares

Balance Sheet

Concept 2024 Q3 2024 Q2
SHORT-TERM ASSETS
Cash & Short-Term Investments $19.82M $22.55M
YoY Change -16.88% -12.57%
Cash & Equivalents $3.743M $5.553M
Short-Term Investments $16.08M $17.00M
Other Short-Term Assets $588.8K $297.1K
YoY Change -18.22% -76.62%
Inventory
Prepaid Expenses
Receivables $91.48K $63.64K
Other Receivables $0.00 $0.00
Total Short-Term Assets $20.50M $22.91M
YoY Change -16.7% -15.41%
LONG-TERM ASSETS
Property, Plant & Equipment $170.6K $99.07K
YoY Change 48.46% -19.24%
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets $23.75K $23.75K
YoY Change 0.0% 0.0%
Total Long-Term Assets $194.4K $122.8K
YoY Change 40.16% -96.39%
TOTAL ASSETS
Total Short-Term Assets $20.50M $22.91M
Total Long-Term Assets $194.4K $122.8K
Total Assets $20.70M $23.03M
YoY Change -16.38% -24.44%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable $285.3K $448.8K
YoY Change -74.08% -13.29%
Accrued Expenses $1.292M $1.233M
YoY Change 13.33% -5.81%
Deferred Revenue
YoY Change
Short-Term Debt $0.00 $0.00
YoY Change
Long-Term Debt Due
YoY Change
Total Short-Term Liabilities $1.581M $1.824M
YoY Change -29.45% -0.18%
LONG-TERM LIABILITIES
Long-Term Debt $0.00 $0.00
YoY Change
Other Long-Term Liabilities
YoY Change
Total Long-Term Liabilities $0.00 $0.00
YoY Change -100.0% -100.0%
TOTAL LIABILITIES
Total Short-Term Liabilities $1.581M $1.824M
Total Long-Term Liabilities $0.00 $0.00
Total Liabilities $1.581M $1.824M
YoY Change -30.37% -5.57%
SHAREHOLDERS EQUITY
Retained Earnings -$201.6M -$199.3M
YoY Change 2.05% 4.45%
Common Stock $8.863K $8.863K
YoY Change 0.03% 0.12%
Preferred Stock
YoY Change
Treasury Stock (at cost) $40.71K $40.71K
YoY Change 0.0% 0.0%
Treasury Stock Shares
Shareholders Equity $19.12M $21.21M
YoY Change
Total Liabilities & Shareholders Equity $20.70M $23.03M
YoY Change -16.38% -24.44%

Cashflow Statement

Concept 2024 Q3 2024 Q2
OPERATING ACTIVITIES
Net Income -$2.219M -$3.069M
YoY Change -66.64% -13.53%
Depreciation, Depletion And Amortization $8.520K $8.510K
YoY Change -14.8% 5.19%
Cash From Operating Activities -$2.833M -$2.498M
YoY Change 8.96% -24.53%
INVESTING ACTIVITIES
Capital Expenditures $80.07K
YoY Change
Acquisitions
YoY Change
Other Investing Activities $1.103M $4.752M
YoY Change -11.09% 33.48%
Cash From Investing Activities $1.022M $4.752M
YoY Change -17.54% 33.48%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities 0.000 217.4K
YoY Change -100.0% -4281.54%
NET CHANGE
Cash From Operating Activities -2.833M -2.498M
Cash From Investing Activities 1.022M 4.752M
Cash From Financing Activities 0.000 217.4K
Net Change In Cash -1.810M 2.472M
YoY Change 92.6% 906.85%
FREE CASH FLOW
Cash From Operating Activities -$2.833M -$2.498M
Capital Expenditures $80.07K
Free Cash Flow -$2.913M
YoY Change 12.04%

Facts In Submission

Frame Concept Type Concept / XBRL Key Value Unit
LPCN Revenue Recognition Services Licensing Fee
RevenueRecognitionServicesLicensingFee
54990 usd
CY2024Q2 us-gaap Revenues
Revenues
89565 usd
dei Document Fiscal Period Focus
DocumentFiscalPeriodFocus
Q2
dei Entity Central Index Key
EntityCentralIndexKey
0001535955
CY2024Q2 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
usd
CY2024Q2 LPCN Revenue Recognition Services Licensing Fee
RevenueRecognitionServicesLicensingFee
usd
CY2023Q2 LPCN Revenue Recognition Services Licensing Fee
RevenueRecognitionServicesLicensingFee
usd
CY2023Q2 LPCN Royalty Revenue
RoyaltyRevenue
usd
LPCN Royalty Revenue
RoyaltyRevenue
usd
CY2023Q2 us-gaap Revenues
Revenues
usd
CY2023Q2 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
usd
CY2024Q2 us-gaap Preferred Stock Dividends Income Statement Impact
PreferredStockDividendsIncomeStatementImpact
usd
CY2023Q2 us-gaap Preferred Stock Dividends Income Statement Impact
PreferredStockDividendsIncomeStatementImpact
usd
us-gaap Preferred Stock Dividends Income Statement Impact
PreferredStockDividendsIncomeStatementImpact
usd
CY2023Q2 us-gaap Stock Redeemed Or Called During Period Value
StockRedeemedOrCalledDuringPeriodValue
usd
us-gaap Stock Issued During Period Value Stock Dividend
StockIssuedDuringPeriodValueStockDividend
usd
us-gaap Stock Redeemed Or Called During Period Value
StockRedeemedOrCalledDuringPeriodValue
usd
us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
usd
LPCN Issuance Of Series B Preferred Stock
IssuanceOfSeriesBPreferredStock
usd
CY2023Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Nonvested Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber
shares
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Vested In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod
shares
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Forfeited In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod
shares
dei Document Type
DocumentType
10-Q
dei Document Quarterly Report
DocumentQuarterlyReport
true
dei Document Period End Date
DocumentPeriodEndDate
2024-06-30
dei Document Fiscal Year Focus
DocumentFiscalYearFocus
2024
dei Document Transition Report
DocumentTransitionReport
false
dei Entity File Number
EntityFileNumber
001-36357
dei Entity Registrant Name
EntityRegistrantName
LIPOCINE INC.
dei Entity Incorporation State Country Code
EntityIncorporationStateCountryCode
DE
dei Entity Tax Identification Number
EntityTaxIdentificationNumber
99-0370688
dei Entity Address Address Line1
EntityAddressAddressLine1
675 Arapeen Drive
dei Entity Address Address Line2
EntityAddressAddressLine2
Suite 202
dei Entity Address City Or Town
EntityAddressCityOrTown
Salt Lake City
dei Entity Address State Or Province
EntityAddressStateOrProvince
UT
dei Entity Address Postal Zip Code
EntityAddressPostalZipCode
84108
dei City Area Code
CityAreaCode
801
dei Local Phone Number
LocalPhoneNumber
994-7383
dei Security12b Title
Security12bTitle
Common Stock, par value $0.0001 per share
dei Trading Symbol
TradingSymbol
LPCN
dei Security Exchange Name
SecurityExchangeName
NASDAQ
dei Entity Current Reporting Status
EntityCurrentReportingStatus
Yes
dei Entity Interactive Data Current
EntityInteractiveDataCurrent
Yes
dei Entity Filer Category
EntityFilerCategory
Non-accelerated Filer
dei Entity Small Business
EntitySmallBusiness
true
dei Entity Emerging Growth Company
EntityEmergingGrowthCompany
false
dei Entity Shell Company
EntityShellCompany
false
CY2024Q3 dei Entity Common Stock Shares Outstanding
EntityCommonStockSharesOutstanding
5347940 shares
CY2024Q2 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
5553371 usd
CY2024Q2 us-gaap Available For Sale Securities Debt Securities Current
AvailableForSaleSecuritiesDebtSecuritiesCurrent
16995424 usd
CY2024Q2 us-gaap Interest Receivable Current
InterestReceivableCurrent
63636 usd
CY2024Q2 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
297051 usd
CY2024Q2 us-gaap Assets Current
AssetsCurrent
22909482 usd
CY2024Q2 us-gaap Accumulated Depreciation Depletion And Amortization Property Plant And Equipment
AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
1199215 usd
CY2023Q4 us-gaap Accumulated Depreciation Depletion And Amortization Property Plant And Equipment
AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
1182191 usd
CY2024Q2 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
99071 usd
CY2024Q2 us-gaap Other Assets Noncurrent
OtherAssetsNoncurrent
23753 usd
CY2024Q2 us-gaap Assets
Assets
23032306 usd
CY2024Q2 us-gaap Accounts Payable Current
AccountsPayableCurrent
448798 usd
CY2024Q2 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
1233477 usd
CY2024Q2 us-gaap Warrants And Rights Outstanding
WarrantsAndRightsOutstanding
141668 usd
CY2024Q2 us-gaap Liabilities Current
LiabilitiesCurrent
1823943 usd
CY2024Q2 us-gaap Liabilities
Liabilities
1823943 usd
CY2024Q2 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.0001
CY2023Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.0001
CY2024Q2 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
200000000 shares
CY2023Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
200000000 shares
CY2024Q2 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
5348276 shares
CY2023Q4 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
5316166 shares
CY2024Q2 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
5347940 shares
CY2023Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
5315830 shares
CY2024Q2 us-gaap Common Stock Value
CommonStockValue
8863 usd
CY2024Q2 us-gaap Additional Paid In Capital
AdditionalPaidInCapital
220582158 usd
CY2024Q2 us-gaap Treasury Stock Value
TreasuryStockValue
40712 usd
CY2024Q2 us-gaap Accumulated Other Comprehensive Income Loss Net Of Tax
AccumulatedOtherComprehensiveIncomeLossNetOfTax
-9719 usd
CY2023Q4 us-gaap Accumulated Other Comprehensive Income Loss Net Of Tax
AccumulatedOtherComprehensiveIncomeLossNetOfTax
7259 usd
CY2024Q2 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-199332227 usd
CY2023Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-199777214 usd
CY2024Q2 us-gaap Stockholders Equity
StockholdersEquity
21208363 usd
CY2023Q4 us-gaap Stockholders Equity
StockholdersEquity
20369443 usd
CY2024Q2 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
23032306 usd
CY2023Q4 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
23001072 usd
LPCN Revenue Recognition Services Licensing Fee
RevenueRecognitionServicesLicensingFee
7500000 usd
CY2024Q2 LPCN Royalty Revenue
RoyaltyRevenue
89565 usd
LPCN Royalty Revenue
RoyaltyRevenue
206738 usd
us-gaap Revenues
Revenues
7706738 usd
us-gaap Revenues
Revenues
54990 usd
CY2024Q2 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
1874721 usd
CY2023Q2 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
2515211 usd
us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
4693646 usd
us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
5621521 usd
CY2024Q2 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
1507412 usd
CY2023Q2 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
1440394 usd
us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
3083131 usd
us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
2727708 usd
CY2024Q2 us-gaap Operating Expenses
OperatingExpenses
3382133 usd
CY2023Q2 us-gaap Operating Expenses
OperatingExpenses
3955605 usd
us-gaap Operating Expenses
OperatingExpenses
7776777 usd
us-gaap Operating Expenses
OperatingExpenses
8349229 usd
CY2024Q2 us-gaap Operating Income Loss
OperatingIncomeLoss
-3292568 usd
CY2023Q2 us-gaap Operating Income Loss
OperatingIncomeLoss
-3955605 usd
us-gaap Operating Income Loss
OperatingIncomeLoss
-70039 usd
us-gaap Operating Income Loss
OperatingIncomeLoss
-8294239 usd
CY2024Q2 us-gaap Investment Income Interest
InvestmentIncomeInterest
308845 usd
CY2023Q2 us-gaap Investment Income Interest
InvestmentIncomeInterest
379521 usd
us-gaap Investment Income Interest
InvestmentIncomeInterest
640209 usd
us-gaap Investment Income Interest
InvestmentIncomeInterest
749991 usd
CY2024Q2 us-gaap Unrealized Gain Loss On Derivatives
UnrealizedGainLossOnDerivatives
-84430 usd
CY2023Q2 us-gaap Unrealized Gain Loss On Derivatives
UnrealizedGainLossOnDerivatives
27455 usd
us-gaap Unrealized Gain Loss On Derivatives
UnrealizedGainLossOnDerivatives
-124502 usd
us-gaap Unrealized Gain Loss On Derivatives
UnrealizedGainLossOnDerivatives
125589 usd
CY2024Q2 us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
224415 usd
CY2023Q2 us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
406976 usd
us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
515707 usd
us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
875580 usd
CY2024Q2 us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
-3068153 usd
CY2023Q2 us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
-3548629 usd
us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
445668 usd
us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
-7418659 usd
CY2024Q2 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
481 usd
us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
681 usd
us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
200 usd
CY2024Q2 us-gaap Net Income Loss
NetIncomeLoss
-3068634 usd
CY2023Q2 us-gaap Net Income Loss
NetIncomeLoss
-3548629 usd
us-gaap Net Income Loss
NetIncomeLoss
444987 usd
us-gaap Net Income Loss
NetIncomeLoss
-7418859 usd
us-gaap Preferred Stock Dividends Income Statement Impact
PreferredStockDividendsIncomeStatementImpact
89 usd
CY2024Q2 us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
-3068634 usd
CY2023Q2 us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
-3548629 usd
us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
444987 usd
us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
-7418948 usd
CY2024Q2 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.57
CY2023Q2 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.68
us-gaap Earnings Per Share Basic
EarningsPerShareBasic
0.08
us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-1.42
CY2024Q2 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
5343922 shares
CY2023Q2 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
5234830 shares
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
5329876 shares
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
5234830 shares
CY2024Q2 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.56
CY2023Q2 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.68
us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
0.10
us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-1.44
CY2024Q2 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
5343922 shares
CY2023Q2 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
5234830 shares
us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
5459204 shares
us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
5234830 shares
CY2024Q2 us-gaap Net Income Loss
NetIncomeLoss
-3068634 usd
CY2023Q2 us-gaap Net Income Loss
NetIncomeLoss
-3548629 usd
us-gaap Net Income Loss
NetIncomeLoss
444987 usd
us-gaap Net Income Loss
NetIncomeLoss
-7418859 usd
CY2024Q2 us-gaap Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
885 usd
CY2023Q2 us-gaap Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
-19053 usd
us-gaap Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
-16978 usd
us-gaap Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
4509 usd
CY2024Q2 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-3067749 usd
CY2023Q2 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-3567682 usd
us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
428009 usd
us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-7414350 usd
CY2023Q1 us-gaap Stockholders Equity
StockholdersEquity
31960028 usd
CY2023Q2 us-gaap Net Income Loss
NetIncomeLoss
-3548629 usd
CY2023Q2 us-gaap Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
-19053 usd
CY2023Q2 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
164865 usd
CY2023Q2 us-gaap Adjustments To Additional Paid In Capital Stock Issued Issuance Costs
AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts
5200 usd
CY2023Q2 us-gaap Stockholders Equity
StockholdersEquity
28552011 usd
CY2022Q4 us-gaap Stockholders Equity
StockholdersEquity
35634940 usd
us-gaap Net Income Loss
NetIncomeLoss
-7418859 usd
us-gaap Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
4509 usd
us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
342637 usd
us-gaap Stock Issued During Period Value New Issues
StockIssuedDuringPeriodValueNewIssues
-11216 usd
CY2023Q2 us-gaap Stockholders Equity
StockholdersEquity
28552011 usd
CY2024Q1 us-gaap Stockholders Equity
StockholdersEquity
23956407 usd
CY2024Q2 us-gaap Net Income Loss
NetIncomeLoss
-3068634 usd
CY2024Q2 us-gaap Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
885 usd
CY2024Q2 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
102265 usd
CY2024Q2 us-gaap Stock Issued During Period Value New Issues
StockIssuedDuringPeriodValueNewIssues
217440 usd
CY2024Q2 us-gaap Stockholders Equity
StockholdersEquity
21208363 usd
CY2023Q4 us-gaap Stockholders Equity
StockholdersEquity
20369443 usd
CY2023Q4 us-gaap Stockholders Equity
StockholdersEquity
20369443 usd
us-gaap Net Income Loss
NetIncomeLoss
444987 usd
us-gaap Net Income Loss
NetIncomeLoss
444987 usd
us-gaap Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
-16978 usd
us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
201571 usd
us-gaap Stock Issued During Period Value New Issues
StockIssuedDuringPeriodValueNewIssues
209340 usd
CY2024Q2 us-gaap Stockholders Equity
StockholdersEquity
21208363 usd
CY2024Q2 us-gaap Stockholders Equity
StockholdersEquity
21208363 usd
us-gaap Net Income Loss
NetIncomeLoss
444987 usd
us-gaap Net Income Loss
NetIncomeLoss
-7418859 usd
us-gaap Depreciation And Amortization
DepreciationAndAmortization
17024 usd
us-gaap Depreciation And Amortization
DepreciationAndAmortization
12910 usd
us-gaap Share Based Compensation
ShareBasedCompensation
201571 usd
us-gaap Share Based Compensation
ShareBasedCompensation
342637 usd
us-gaap Fair Value Adjustment Of Warrants
FairValueAdjustmentOfWarrants
124502 usd
us-gaap Fair Value Adjustment Of Warrants
FairValueAdjustmentOfWarrants
-125589 usd
us-gaap Accretion Amortization Of Discounts And Premiums Investments
AccretionAmortizationOfDiscountsAndPremiumsInvestments
411145 usd
us-gaap Accretion Amortization Of Discounts And Premiums Investments
AccretionAmortizationOfDiscountsAndPremiumsInvestments
508425 usd
us-gaap Increase Decrease In Accrued Interest Receivable Net
IncreaseDecreaseInAccruedInterestReceivableNet
11382 usd
us-gaap Increase Decrease In Accrued Interest Receivable Net
IncreaseDecreaseInAccruedInterestReceivableNet
-56197 usd
LPCN Issuance Of Series B Preferred Stock
IssuanceOfSeriesBPreferredStock
89 usd
CY2024Q2 us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
-3068634 usd
CY2023Q2 us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
-3548629 usd
us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
444987 usd
us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
-7418948 usd
CY2024Q2 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
5343922 shares
CY2023Q2 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
5234830 shares
CY2024Q2 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.57
CY2023Q2 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.68
CY2024Q2 us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
-3068634 usd
CY2023Q2 us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
-3548629 usd
us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
444987 usd
us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
-7418948 usd
CY2024Q2 us-gaap Unrealized Gain Loss On Derivatives
UnrealizedGainLossOnDerivatives
-84430 usd
CY2023Q2 us-gaap Unrealized Gain Loss On Derivatives
UnrealizedGainLossOnDerivatives
27455 usd
CY2024Q2 us-gaap Net Income Loss Available To Common Stockholders Diluted
NetIncomeLossAvailableToCommonStockholdersDiluted
-2984204 usd
CY2023Q2 us-gaap Net Income Loss Available To Common Stockholders Diluted
NetIncomeLossAvailableToCommonStockholdersDiluted
-3576084 usd
CY2024Q2 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
5343922 shares
CY2023Q2 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
5234830 shares
CY2024Q2 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
5343922 shares
CY2023Q2 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
5234830 shares
CY2024Q2 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.56
CY2023Q2 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.68
CY2024Q2 us-gaap Available For Sale Debt Securities Amortized Cost Basis
AvailableForSaleDebtSecuritiesAmortizedCostBasis
17005143 usd
CY2024Q2 us-gaap Available For Sale Debt Securities Accumulated Gross Unrealized Gain Before Tax
AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
98 usd
CY2024Q2 us-gaap Available For Sale Debt Securities Accumulated Gross Unrealized Loss Before Tax
AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
9817 usd
CY2024Q2 us-gaap Available For Sale Securities Debt Securities
AvailableForSaleSecuritiesDebtSecurities
16995424 usd
CY2023Q4 us-gaap Available For Sale Debt Securities Amortized Cost Basis
AvailableForSaleDebtSecuritiesAmortizedCostBasis
17256529 usd
CY2023Q4 us-gaap Available For Sale Debt Securities Accumulated Gross Unrealized Gain Before Tax
AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
8574 usd
CY2023Q4 us-gaap Available For Sale Debt Securities Accumulated Gross Unrealized Loss Before Tax
AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
1315 usd
CY2023Q4 us-gaap Available For Sale Securities Debt Securities
AvailableForSaleSecuritiesDebtSecurities
17263788 usd
CY2024Q2 us-gaap Available For Sale Securities Debt Maturities Within One Year Amortized Cost
AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearAmortizedCost
17005143 usd
CY2024Q2 us-gaap Available For Sale Securities Debt Maturities Within One Year Fair Value
AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue
16995424 usd
CY2024Q2 us-gaap Available For Sale Securities Debt Maturities Single Maturity Date Amortized Cost Basis
AvailableForSaleSecuritiesDebtMaturitiesSingleMaturityDateAmortizedCostBasis
17005143 usd
CY2024Q2 us-gaap Available For Sale Securities Debt Maturities Single Maturity Date
AvailableForSaleSecuritiesDebtMaturitiesSingleMaturityDate
16995424 usd
CY2024Q2 us-gaap Proceeds From Sale Of Held To Maturity Securities
ProceedsFromSaleOfHeldToMaturitySecurities
0 usd
CY2023Q2 us-gaap Proceeds From Sale Of Held To Maturity Securities
ProceedsFromSaleOfHeldToMaturitySecurities
0 usd
us-gaap Proceeds From Sale Of Held To Maturity Securities
ProceedsFromSaleOfHeldToMaturitySecurities
0 usd
us-gaap Proceeds From Sale Of Held To Maturity Securities
ProceedsFromSaleOfHeldToMaturitySecurities
0 usd
CY2024Q2 us-gaap Debt And Equity Securities Realized Gain Loss
DebtAndEquitySecuritiesRealizedGainLoss
0 usd
CY2023Q2 us-gaap Debt And Equity Securities Realized Gain Loss
DebtAndEquitySecuritiesRealizedGainLoss
0 usd
us-gaap Debt And Equity Securities Realized Gain Loss
DebtAndEquitySecuritiesRealizedGainLoss
0 usd
us-gaap Debt And Equity Securities Realized Gain Loss
DebtAndEquitySecuritiesRealizedGainLoss
0 usd
CY2024Q2 us-gaap Proceeds From Sale And Maturity Of Marketable Securities
ProceedsFromSaleAndMaturityOfMarketableSecurities
11500000 usd
CY2023Q2 us-gaap Proceeds From Sale And Maturity Of Marketable Securities
ProceedsFromSaleAndMaturityOfMarketableSecurities
5900000 usd
us-gaap Proceeds From Sale And Maturity Of Marketable Securities
ProceedsFromSaleAndMaturityOfMarketableSecurities
18200000 usd
us-gaap Proceeds From Sale And Maturity Of Marketable Securities
ProceedsFromSaleAndMaturityOfMarketableSecurities
17900000 usd
CY2024Q2 LPCN Other Than Temporary Impairment Credit Losses Recognized In Earnings Additions No Previous Impairments
OtherThanTemporaryImpairmentCreditLossesRecognizedInEarningsAdditionsNoPreviousImpairments
0 usd
CY2023Q2 LPCN Other Than Temporary Impairment Credit Losses Recognized In Earnings Additions No Previous Impairments
OtherThanTemporaryImpairmentCreditLossesRecognizedInEarningsAdditionsNoPreviousImpairments
0 usd
LPCN Other Than Temporary Impairment Credit Losses Recognized In Earnings Additions No Previous Impairments
OtherThanTemporaryImpairmentCreditLossesRecognizedInEarningsAdditionsNoPreviousImpairments
0 usd
LPCN Other Than Temporary Impairment Credit Losses Recognized In Earnings Additions No Previous Impairments
OtherThanTemporaryImpairmentCreditLossesRecognizedInEarningsAdditionsNoPreviousImpairments
0 usd
CY2024Q2 us-gaap Assets Fair Value Disclosure
AssetsFairValueDisclosure
22744948 usd
CY2024Q2 us-gaap Fair Value Net Asset Liability
FairValueNetAssetLiability
22886616 usd
CY2023Q4 us-gaap Assets Fair Value Disclosure
AssetsFairValueDisclosure
21959279 usd
CY2023Q4 us-gaap Fair Value Net Asset Liability
FairValueNetAssetLiability
21976445 usd
LPCN Revenue Reversal Of Variable Consideration
RevenueReversalOfVariableConsideration
7500000 usd
us-gaap Royalty Income Nonoperating
RoyaltyIncomeNonoperating
140000 usd
CY2024Q2 us-gaap Research And Development Expense Excluding Acquired In Process Cost
ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost
1100000 usd
CY2023Q2 us-gaap Research And Development Expense Excluding Acquired In Process Cost
ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost
1700000 usd
us-gaap Research And Development Expense Excluding Acquired In Process Cost
ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost
2900000 usd
us-gaap Research And Development Expense Excluding Acquired In Process Cost
ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost
3800000 usd
CY2024Q2 us-gaap Lessee Operating Lease Liability Payments Remainder Of Fiscal Year
LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear
184038 usd
CY2024Q2 us-gaap Lessee Operating Lease Liability Payments Due Next Twelve Months
LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths
61346 usd
CY2024Q2 us-gaap Lessee Operating Lease Liability Payments Due
LesseeOperatingLeaseLiabilityPaymentsDue
245384 usd
CY2024Q2 us-gaap Payments For Rent
PaymentsForRent
92000 usd
CY2023Q2 us-gaap Payments For Rent
PaymentsForRent
89000 usd
us-gaap Payments For Rent
PaymentsForRent
182000 usd
us-gaap Payments For Rent
PaymentsForRent
176000 usd
CY2023Q2 us-gaap Stockholders Equity Reverse Stock Split
StockholdersEquityReverseStockSplit
reverse stock split ratio of 1-for-17
CY2024Q2 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
200000000 shares
CY2023Q2 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
200000000 shares
CY2024Q2 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.0001
CY2023Q2 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.0001
CY2015Q4 us-gaap Preferred Stock Redemption Price Per Share
PreferredStockRedemptionPricePerShare
63.96
CY2024Q2 us-gaap Preferred Stock Redemption Price Per Share
PreferredStockRedemptionPricePerShare
0.001
CY2024Q2 us-gaap Share Based Compensation
ShareBasedCompensation
102000 usd
CY2023Q2 us-gaap Share Based Compensation
ShareBasedCompensation
165000 usd
CY2024Q2 us-gaap Share Based Compensation
ShareBasedCompensation
102265 usd
CY2023Q2 us-gaap Share Based Compensation
ShareBasedCompensation
164865 usd
us-gaap Share Based Compensation
ShareBasedCompensation
201571 usd
us-gaap Share Based Compensation
ShareBasedCompensation
342637 usd
CY2024Q2 us-gaap Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized
EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized
384000 usd
us-gaap Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized Period For Recognition1
EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1
P0Y9M18D
CY2024Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
295517 shares
us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2
P6Y6M18D
CY2024Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
30.36
CY2024Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue
230307 usd
CY2024Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber
224887 shares
us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Weighted Average Remaining Contractual Term1
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1
P5Y9M14D
CY2024Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice
37.54
CY2024Q2 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Intrinsic Value1
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1
77671 usd
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Grants In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod
21762 shares
CY2024Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Nonvested Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber
21762 shares
CY2023Q4 us-gaap Warrants And Rights Outstanding
WarrantsAndRightsOutstanding
17166 usd
us-gaap Fair Value Adjustment Of Warrants
FairValueAdjustmentOfWarrants
124502 usd
CY2024Q2 us-gaap Warrants And Rights Outstanding
WarrantsAndRightsOutstanding
141668 usd
CY2019Q4 us-gaap Payments For Legal Settlements
PaymentsForLegalSettlements
1250000 usd
CY2024Q2 ecd Rule10b51 Arr Adopted Flag
Rule10b51ArrAdoptedFlag
false
CY2024Q2 ecd Non Rule10b51 Arr Adopted Flag
NonRule10b51ArrAdoptedFlag
false
CY2024Q2 ecd Rule10b51 Arr Trmntd Flag
Rule10b51ArrTrmntdFlag
false
CY2024Q2 ecd Non Rule10b51 Arr Trmntd Flag
NonRule10b51ArrTrmntdFlag
false

Files In Submission

Name View Source Status
0001493152-24-030648-index-headers.html Edgar Link pending
0001493152-24-030648-index.html Edgar Link pending
0001493152-24-030648.txt Edgar Link pending
0001493152-24-030648-xbrl.zip Edgar Link pending
ex31-1.htm Edgar Link pending
ex31-2.htm Edgar Link pending
FilingSummary.xml Edgar Link unprocessable
ex32-1.htm Edgar Link pending
ex32-2.htm Edgar Link pending
Financial_Report.xlsx Edgar Link pending
form10-q.htm Edgar Link pending
form10-q_001.jpg Edgar Link pending
lpcn-20240630.xsd Edgar Link pending
MetaLinks.json Edgar Link pending
R1.htm Edgar Link pending
R10.htm Edgar Link pending
R11.htm Edgar Link pending
R12.htm Edgar Link pending
R13.htm Edgar Link pending
R14.htm Edgar Link pending
R15.htm Edgar Link pending
R16.htm Edgar Link pending
R17.htm Edgar Link pending
R18.htm Edgar Link pending
R19.htm Edgar Link pending
R2.htm Edgar Link pending
R20.htm Edgar Link pending
R21.htm Edgar Link pending
R22.htm Edgar Link pending
R23.htm Edgar Link pending
R24.htm Edgar Link pending
R25.htm Edgar Link pending
R26.htm Edgar Link pending
R27.htm Edgar Link pending
R28.htm Edgar Link pending
R29.htm Edgar Link pending
R3.htm Edgar Link pending
R30.htm Edgar Link pending
R31.htm Edgar Link pending
R32.htm Edgar Link pending
R33.htm Edgar Link pending
R34.htm Edgar Link pending
R35.htm Edgar Link pending
R36.htm Edgar Link pending
R37.htm Edgar Link pending
R38.htm Edgar Link pending
R39.htm Edgar Link pending
R4.htm Edgar Link pending
R40.htm Edgar Link pending
R41.htm Edgar Link pending
R42.htm Edgar Link pending
R43.htm Edgar Link pending
R44.htm Edgar Link pending
lpcn-20240630_cal.xml Edgar Link unprocessable
lpcn-20240630_def.xml Edgar Link unprocessable
lpcn-20240630_lab.xml Edgar Link unprocessable
lpcn-20240630_pre.xml Edgar Link unprocessable
form10-q_htm.xml Edgar Link completed
R45.htm Edgar Link pending
R46.htm Edgar Link pending
R47.htm Edgar Link pending
R48.htm Edgar Link pending
R5.htm Edgar Link pending
R6.htm Edgar Link pending
R7.htm Edgar Link pending
R8.htm Edgar Link pending
R9.htm Edgar Link pending
report.css Edgar Link pending
Show.js Edgar Link pending